HRPT2 (CDC73) (NM_024529) Human Mass Spec Standard

CAT#: PH309479

CDC73 MS Standard C13 and N15-labeled recombinant protein (NP_078805)



  View other "HRPT2" proteins (3)

Need it in bulk or customized?
Get a free quote

CNY 19,520.00


货期*
4周

规格
    • 10 ug

Product images

经常一起买 (2)
Transient overexpression lysate of cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) (CDC73)
    • 100 ug

CNY 3,080.00


Rabbit Polyclonal Cdc73 Antibody
    • 50 ug

CNY 6,098.00

Specifications

Product Data
Description CDC73 MS Standard C13 and N15-labeled recombinant protein (NP_078805)
Species Human
Expression Host HEK293
Expression cDNA Clone or AA Sequence RC209479
Predicted MW 60.6 kDa
Protein Sequence
Tag C-Myc/DDK
Purity > 80% as determined by SDS-PAGE and Coomassie blue staining
Concentration >0.05 µg/µL as determined by microplate BCA method
Labeling Method Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine
Buffer 25 mM Tris-HCl, 100 mM glycine, pH 7.3
Reference Data
RefSeq NP_078805
RefSeq Size 5942
RefSeq ORF 1593
Synonyms C1orf28; FIHP; HPTJT; HRPT1; HRPT2; HYX
Locus ID 79577
Cytogenetics 1q31.2
Summary This gene encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3' mRNA processing factors with actively-transcribed chromatin. Mutations in this gene have been linked to hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma. [provided by RefSeq, Jul 2009]
Protein Families Druggable Genome
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...